Skip to main content

Table 1 The comparison of control subjects and patients with HIV

From: Trabecular bone scores in young HIV-infected men: a matched case-control study

Variables (N (%) or mean ± SD)Control (N = 80)HIV (N = 80)P-value
Demographic findings
 Age (years)39 ± 839 ± 80.693
 BMI (kg/m2)24.9 ± 3.322.9 ± 3.0< 0.001
 Currently smoking44 (55)36 (45.0)0.081
 Alcohol ≥3 units/day3 (4)3 (4)1.000
 Previous fracture1 (1)10 (12.5)0.009
 Underlying disease
  Diabetes mellitus0 (0)3 (3.8)0.245
  Hypertension0 (0)4 (5.0)0.120
  Dyslipidemia0 (0)8 (10.0)0.028
Laboratory findings
 Urea nitrogen (mg/dl)13.9 ± 2.813.2 ± 3.50.154
 Creatinine (mg/dl)0.9 ± 0.10.9 ± 0.10.928
 Calcium (mg/dl)9.1 ± 0.89.1 ± 0.30.470
 Phosphorus (mg/dl)3.6 ± 1.53.3 ± 0.50.130
 ESR (mm/h)7.4 ± 5.49.6 ± 9.00.081
 Hemoglobin (g/dl)15.6 ± 1.115.3 ± 1.00.041
 Platelet (103/μl)245 ± 59228 ± 390.033
HIV-specific factors
 Duration since HIV diagnosis (days) 2622.9 ± 1814.9 
 Nadir CD4 T-cell counts (cells/μl) 349 ± 183 
 Current CD4 count (cells/μl) 669 ± 271 
 Current proportion with plasma HIV-1 RNA viral load < 40 copies/ml 75 (93.7%) 
 On ART 78 (97.5%) 
 On TDF 40 (50.0%) 
 Current ART
  NNRTI-based 28 
  PI-based 29 
  Integrase inhibitor-based 21 
 Duration of ART (days) 677.9 ± 411.2 
  1. SD Standard deviation, BMI Body mass index, ESR Erythrocyte sedimentation rate, ART Antiretroviral therapy, TDF Tenofovir disoproxil fumarate, NNRTI Non-nucleoside reverse transcriptase inhibitors, PI Protease inhibitor